戴维医疗(300314) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥121,163,868.56, a decrease of 22.00% compared to ¥155,328,964.53 in the same period last year[5] - Net profit attributable to shareholders was ¥22,567,669.04, down 40.78% from ¥38,107,228.76 year-on-year[5] - Basic and diluted earnings per share were both ¥0.0784, a decrease of 40.74% from ¥0.1323 in the same period last year[5] - Total operating revenue decreased to ¥121,163,868.56 from ¥155,328,964.53, representing a decline of approximately 22% year-over-year[20] - Net profit for the period was ¥22,567,669.04, down from ¥38,107,228.76, reflecting a decline of approximately 41% year-over-year[21] - Operating profit decreased to ¥25,840,397.43 from ¥44,488,936.73, a drop of around 42% year-over-year[21] - Earnings per share decreased to ¥0.0784 from ¥0.1323, reflecting a decline of approximately 41% year-over-year[22] Cash Flow - The net cash flow from operating activities was -¥32,239,761.88, representing a decline of 212.07% compared to -¥10,331,039.53 in the previous year[5] - Cash flow from operating activities showed a net outflow of ¥32,239,761.88, worsening from a net outflow of ¥10,331,039.53 in the previous period[23] - The net increase in cash and cash equivalents was -$48,415,502.37, compared to -$114,368,823.04 previously, showing a reduction in cash outflow[24] - The ending balance of cash and cash equivalents was $283,145,669.78, down from $443,087,497.54, indicating a decrease in liquidity[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,385,776,038.97, down 1.72% from ¥1,410,082,914.70 at the end of the previous year[5] - The company's total liabilities decreased from CNY 238,393,710.24 to CNY 189,056,321.62, reflecting a decline of about 20.7%[16] - Current liabilities decreased from CNY 232,387,523.93 to CNY 183,984,580.97, a reduction of approximately 20.7%[16] - The company's long-term equity investments decreased from CNY 50,327,967.68 to CNY 48,707,993.03, a decline of about 3.2%[17] - The total non-current assets decreased from CNY 508,368,642.73 to CNY 502,928,305.25, a decrease of approximately 1.1%[17] - Total liabilities decreased to ¥193,896,157.08 from ¥241,765,545.70, a reduction of approximately 20% year-over-year[18] Research and Development - Research and development expenses increased by 35.09% to ¥13,897,552.90 from ¥10,287,345.11 in the previous year[9] - Research and development expenses increased to ¥13,897,552.90 from ¥10,287,345.11, marking a rise of approximately 35% year-over-year[20] Other Income and Investments - The company received government subsidies amounting to ¥3,147,557.99, contributing to other income of ¥3,472,227.93, which increased by 151.35% year-on-year[9] - The company reported a significant increase in investment income, which rose by 213.94% to ¥2,910,678.58 compared to a loss of ¥2,554,623.67 in the previous year[9] - Other income rose to ¥3,472,227.93 from ¥1,381,449.45, an increase of about 152% year-over-year[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,622[11] - The company reported a total of 144,258,552 shares under lock-up agreements, with a release schedule based on the previous year's holdings[14] - The company has a significant number of shares held by major shareholders, with the largest shareholder holding 98,946,150 shares[13] Accounts Receivable and Inventory - Accounts receivable rose by 42.96% to ¥37,774,667.28, primarily due to increased credit limits granted to distributors[9] - Accounts receivable increased from CNY 26,423,040.77 to CNY 37,774,667.28, reflecting an increase of approximately 42.9%[16] - Inventory rose from CNY 182,135,010.43 to CNY 195,169,622.42, indicating an increase of about 7.2%[16]